RT Journal Article
SR Electronic
T1 Development and Performance Assessment of a Novel Plasma p-Tau181 Assay Reflecting Tau Tangle Pathology in Alzheimer’s Disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.09.15.23295595
DO 10.1101/2023.09.15.23295595
A1 Tagai, Kenji
A1 Tatebe, Harutsugu
A1 Matsuura, Sayo
A1 Hong, Zhang
A1 Kokubo, Naomi
A1 Matsuoka, Kiwamu
A1 Endo, Hironobu
A1 Oyama, Asaka
A1 Hirata, Kosei
A1 Shinotoh, Hitoshi
A1 Kataoka, Yuko
A1 Matsumoto, Hideki
A1 Oya, Masaki
A1 Kurose, Shin
A1 Takahata, Keisuke
A1 Ichihashi, Masanori
A1 Kubota, Manabu
A1 Seki, Chie
A1 Shimada, Hitoshi
A1 Takado, Yuhei
A1 Kawamura, Kazunori
A1 Zhang, Ming-Rong
A1 Soeda, Yoshiyuki
A1 Takashima, Akihiko
A1 Higuchi, Makoto
A1 Tokuda, Takahiko
YR 2023
UL http://medrxiv.org/content/early/2023/11/20/2023.09.15.23295595.abstract
AB Several blood-based assays for phosphorylated tau (p-tau) have been developed to detect brain tau pathologies in Alzheimer’s disease (AD). However, plasma p-tau measured by currently available assays is influenced by brain amyloid and, therefore, could not accurately reflect brain tau deposits. Here, we devised a novel immunoassay that can quantify N- and C-terminally truncated p-tau fragments (mid-p-tau181) in human plasma. We measured plasma p-tau181 levels in 164 participants who underwent both amyloid and tau positron emission tomography (PET) scans using mid-p-tau181 and conventional p-tau181 assays. The mid-p-tau181 assay displayed stronger correlations with tau PET accumulation than the conventional assay in the AD continuum and accurately distinguished between tau PET-positive and -negative cases. Furthermore, the mid-p-tau181 assay demonstrated a trajectory similar to tau PET alongside cognitive decline. Consequently, our mid-p-tau181 assay could be useful in evaluating the extent of brain tau burden in AD.Competing Interest StatementHitoshi Shimada, Ming-Rong Zhang, and Makoto Higuchi hold patents on compounds related to the present report (JP 5422782/EP 12 884 742.3/CA2894994/HK1208672).Clinical TrialUMIN000041383Funding StatementThis study was supported in part by AMED under Grant Numbers JP18dm0207018, JP19dm0207072, JP18dk0207026, JP19dk0207049, 21wm0425015h0001, and 20356533; MEXT KAKENHI under Grant Numbers JP16H05324 and JP18K07543; JST under Grant Numbers JPMJCR1652 and JPMJMS2024; and the Kao Research Council for the Study of Healthcare Science, Biogen Idec Inc. and APRINOIA Therapeutics.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Certified Review Board of National Institutes for Quantum Science and Technology gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data supporting this study’s findings are available from the corresponding author on reasonable request. Sharing and reuse of data require the expressed written permission of the authors, as well as clearance from the Institutional Review Boards.